Skip to main content

Alprazolam-induced dose-dependent anorgasmia: case analysis

  • Kenneth R. Kaufman (a1), Melissa Coluccio (a2), Michelle Linke (a2), Elizabeth Noonan (a3), Ronke Babalola (a2) and Rehan Aziz (a4)...

Sexual dysfunctions are associated with multiple medical and psychiatric disorders, as well as pharmacotherapies used to treat these disorders. Although sexual dysfunctions negatively affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and clinicians do not pose directed questions to determine their presence or severity. This issue is especially important in psychiatric patients, for whom most common psychotropics may cause sexual dysfunctions (antidepressants, antipsychotics, anxiolytics and mood-stabilising agents). There is limited literature addressing benzodiazepines, and alprazolam in particular.


To report dose-dependent alprazolam anorgasmia.


Case analysis with PubMed literature review.


A 30-year-old male psychiatric patient presented with new-onset anorgasmia in the context of asymptomatic generalised anxiety disorder, social anxiety, panic disorder with agoraphobia, obsessive–compulsive disorder, major depression in remission, and attention-deficit hyperactivity disorder treated with escitalopram 10 mg q.a.m., gabapentin 1000 mg total daily dose, lisdexamfetamine dimesylate 70 mg q.a.m., nortriptyline 60 mg q.h.s. and alprazolam extended-release 2.5 mg total daily dose. All psychotropic doses had been constant for >6 months excluding alprazolam, which was titrated from 1 mg to 2.5 mg total daily dose. The patient denied any sexual dysfunction with alprazolam at 1 mg q.d. and 1 mg b.i.d. Within 1 week of increasing alprazolam to 2.5 mg total daily dose, the patient reported anorgasmia. Anorgasmia was alprazolam dose-dependent, as anorgasmia resolved with reduced weekend dosing (1 mg b.i.d. Saturday/1.5 mg total daily dose Sunday).


Sexual dysfunction is an important adverse effect negatively influencing therapeutic outcome. This case reports alprazolam-induced dose-dependent anorgasmia. Clinicians/patients should be aware of this adverse effect. Routine sexual histories are indicated.

Declaration of interest


  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Alprazolam-induced dose-dependent anorgasmia: case analysis
      Available formats
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Alprazolam-induced dose-dependent anorgasmia: case analysis
      Available formats
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Alprazolam-induced dose-dependent anorgasmia: case analysis
      Available formats
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (, which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Corresponding author
Correspondence: Kenneth R. Kaufman, Departments of Psychiatry, Neurology and Anesthesiology, Rutgers Robert Wood Johnson Medical School, 125 Paterson Street, Suite #2200, New Brunswick, New Jersey 08901, USA. Email:
Hide All
1McCabe, MP, Sharlip, ID, Lewis, R, Atalla, E, Balon, R, Fisher, AD, et al. Risk factors for sexual dysfunction among women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016; 13: 153–67.
2Montejo, AL, Montejo, L, Baldwin, DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry 2018; 17: 311.
3Kaufman, KR, Coluccio, M, Sivaraaman, K, Campeas, M. Lamotrigine-induced sexual dysfunction and noncompliance: case analysis with literature review. BJPsych Open 2017; 3: 249–53.
4Kaufman, KR, Wong, S, Sivaraaman, K, Anim, C, Delatte, D. Epilepsy and AED-induced decreased libido – the unasked psychosocial comorbidity. Epilepsy Behav 2015; 52: 236–8.
5Mitchell, AJ, Selmes, T. Why don't patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatri Treat 2007; 13: 336–46.
6La Torre, A, Giupponi, G, Duffy, D, Conca, A. Sexual dysfunction related to psychotropic drugs: a critical review – part I: antidepressants. Pharmacopsychiatry 2013; 46: 191–9.
7La Torre, A, Conca, A, Duffy, D, Giupponi, G, Pompili, M, Grözinger, M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 2013; 46: 201–8.
8La Torre, A, Giupponi, G, Duffy, DM, Pompili, M, Grözinger, M, Kapfhammer, HP, et al. Sexual dysfunction related to psychotropic drugs: a critical review. Part III: mood stabilizers and anxiolytic drugs. Pharmacopsychiatry 2014; 47: 16.
9Fossey, MD, Hamner, MB. Clonazepam-related sexual dysfunction in male veterans with PTSD. Anxiety 1994–1995; 1: 233–6.
10Shen, WW, Sata, LS. Inhibited female orgasm resulting from psychotropic drugs. A five-year, updated, clinical review. J Reprod Med 1990; 35: 11–4.
11Lydiard, RB, Howell, EF, Laraia, MT, Ballenger, JC. Sexual side effects of alprazolam. Am J Psychiatry 1987; 144: 254–5.
12O'Sullivan, GH, Noshirvani, H, Başoğlu, M, Marks, IM, Swinson, R, Kuch, K, et al. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. Br J Psychiatry 1994; 165: 7986.
13Márquez, M, Arenoso, H, Caruso, N. Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Actas Esp Psiquiatr 2011; 39: 8894.
14McGahuey, CA, Gelenberg, AJ, Laukes, CA, Moreno, FA, Delgado, PL, McKnight, KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26: 2540.
15Naranjo, CA, Shear, NH, Lanctôt, KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992; 32: 897904.
16Kendurkar, A, Kaur, B. Major depressive disorder, obsessive–compulsive disorder, and generalized anxiety disorder: do the sexual dysfunctions differ? Prim Care Companion J Clin Psychiatry 2008; 10: 299305.
17Bodinger, L, Hermesh, H, Aizenberg, D, Valevski, A, Marom, S, Shiloh, R, et al. Sexual function and behavior in social phobia. J Clin Psychiatry 2002; 63: 874–9.
18Aksoy, UM, Aksoy, SG, Maner, F, Gokalp, P, Yanik, M. Sexual dysfunction in obsessive compulsive disorder and panic disorder. Psychiatr Danub 2012; 24: 381–5.
19Blumentals, WA, Gomez-Caminero, A, Brown, RR, Vannappagari, V, Russo, LJ. A case control study of erectile dysfunction among men with panic disorder. Int J Impot Res 2004; 16: 299302.
20Bijlenga, D, Vroege, JA, Stammen, AJM, Breuk, M, Boonstra, AM, van der Rhee, K, et al. Prevalence of sexual dysfunctions and other sexual disorders in adults with attention-deficit/hyperactivity disorder compared to the general population. Atten Defic Hyperact Disord. 2018; 10: 8796.
21Iovino, P, Pascariello, A, Limongelli, P, Tremolaterra, F, Consalvo, D, Sabbatini, F, et al. The prevalence of sexual behavior disorders in patients with treated and untreated gastroesophageal reflux disease. Surg Endosc 2007; 21: 1104–10.
22Katz, A. Obesity and sexual dysfunction: making the connection. Am J Nurs 2017; 117: 4550.
23Serretti, A, Chiesa, A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29: 259–66.
24Strohmaier, J, Wüst, S, Uher, R, Henigsberg, N, Mors, O, Hauser, J, et al. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2011; 12: 528–38.
25Kaufman, KR, Struck, PJ. Gabapentin-induced sexual dysfunction. Epilepsy Behav 2011; 21: 324–6.
26Wright, CE. Clinical pharmacokinetics of alprazolam extended release: a summary. Curr Therap Res 1995; 56: 947–56.
27Glue, P, Fang, A, Gandelman, K, Klee, B. Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. Am J Ther 2006; 13: 418–22.
28Hall, J, Naranjo, CA, Sproule, BA, Herrmann, N. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. J Clin Psychopharmacol 2003; 23: 349–57.
29Goodchild, CS. GABA receptors and benzodiazepines. Br J Anaesth 1993; 71: 127–33.
30Griffin, CE 3rd, Kaye, AM, Bueno, FR, Kaye, AD. Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner J. 2013; 13: 214–23.
31Fernández-Guasti, A, Larsson, K, Beyer, C. GABAergic control of masculine sexual behavior. Pharmacol Biochem Behav 1986; 24: 1065–70.
32Rodríguez-Manzo, G, Canseco-Alba, A. A new role for GABAergic transmission in the control of male rat sexual behavior expression. Behav Brain Res 2017; 320: 21–9.
33Lee, TY, Pan, JT. Involvement of central GABAergic neurons in basal and diurnal changes of tuberoinfundibular dopaminergic neuronal activity and prolactin secretion. Life Sci 2001; 68: 1965–75.
34Hollander, AB, Pastuszak, AW, Hsieh, TC, Johnson, WG, Scovell, JM, Mai, CK, et al. Cabergoline in the treatment of male orgasmic disorder – a retrospective pilot analysis. Sex Med 2016; 4: e2833.
35Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593602.
36Moffitt, TE, Caspi, A, Taylor, A, Kokaua, J, Milne, BJ, Polanczyk, G, et al. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol Med 2010; 40: 899909.
37Moore, TJ, Mattison, DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 2017; 177: 274–5.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Alprazolam-induced dose-dependent anorgasmia: case analysis

  • Kenneth R. Kaufman (a1), Melissa Coluccio (a2), Michelle Linke (a2), Elizabeth Noonan (a3), Ronke Babalola (a2) and Rehan Aziz (a4)...
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *